Hostname: page-component-cd9895bd7-hc48f Total loading time: 0 Render date: 2024-12-28T02:36:09.838Z Has data issue: false hasContentIssue false
  • English
  • Français

P.131 Outcomes of Nusinersen in adult and pediatric cohorts of spinal muscular amyotrophy after two years of usage at the CHU de Québec-Université Laval

Published online by Cambridge University Press:  05 January 2022

M Michel ,
N Chrestian ,
I Demers ,
N Déry ,
A Dionne ,
C Jobin ,
K Lepage ,
V Paquin  and
X Rodrigue
M Michel
Affiliation:
(Québec)
N Chrestian
Affiliation:
(Québec)*
I Demers
Affiliation:
(Québec)
N Déry
Affiliation:
(Québec)
A Dionne
Affiliation:
(Québec)
C Jobin
Affiliation:
(Québec)
K Lepage
Affiliation:
(Québec)
V Paquin
Affiliation:
(Québec)
X Rodrigue
Affiliation:
(Québec)
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Background: Nusinersen is approved for spinal muscular amyotrophy type I,II,III and is available for adult and pediatric populations since January 2019 at the CHU de Québec-UL. Methods: Patients who received at least one dose of nusinersen between January 2019 and March 2021 were included. Required information was gathered from patients’ charts. Results: Ten adults (70 injections) and 23 infants and children (202 injections) were included. No child but two adults stopped the therapy for personal reasons. Tests were performed at 0, 6, 18, 24 months when possible to assess efficacy, tolerability and quality of life perception (Table 1). Preliminary data shows stabilization or improvement for many tests. Conclusions: Nusinersen is well tolerated. Favorable effects were observed in both populations. A monitoring is still imperative for an objective assessment and for evaluation of the most relevant tests. Long term benefits remain to be demonstrated but results are encouraging.

PCFFVCCHOPRULM6MWTHFMSE
Adult✓✓✓✓✓✓
Pediatric✓✓✓✓
HFMSTUGStep testSMARFSPedsQL
Adult✓✓✓
Pediatric✓✓✓✓

Type
Poster Presentations
Information
Canadian Journal of Neurological Sciences , Volume 48 , Supplement s3: Canadian Neurological Sciences Federation (CNSF) 2021 Congress , November 2021 , pp. S57
Copyright
© The Author(s), 2021. Published by Cambridge University Press on behalf of Canadian Neurological Sciences Federation